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Introduction
Cardiovascular disease is the leading cause of death in
developed countries. Premenopausal women have lower
cardiovascular morbidity and mortality than men of a
similar age. However, after menopause, the incidence of
cardiovascular disease increases and the prevalences of
cardiovascular disease in men and women are similar
during the eighth decade of life [1,2]. More than 30
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epidemiologic studies have found that postmenopausal
women who use estrogen are at a lower risk of coronary
disease than those who do not [3]. This further supports
the theory that the female sex hormones have beneficial
effects on cardiovascular disease.
Progestogen added to estrogen reduces or eliminates
the excess risk of endometrial cancer due to the un-
opposed effect of estrogen. The use of progestogens
combined with estrogen is now common, but informa-
tion about the risk of cardiovascular disease associa-
ted with combined therapy is limited. Grodstein et al re-
viewed 59,337 women who participated in the Nurses’
Health Study and suggested that the addition of pro-
gestin did not appear to attenuate the cardiovascular
effects of postmenopausal estrogen therapy [4]. How-
ever, experimental data suggest that the addition of
progestin may diminish the apparent cardioprotec-
tive effects of hormone therapy on lipoprotein metabo-
lism [5,6], arterial dilatation, and blood flow [7]. Fur-
thermore, in the Heart and Estrogen/Progestin Re-
placement Study (HERS) [8], postmenopausal women
with established coronary heart disease who received
estrogen plus progestin did not experience a reduc-
tion in overall risk of adverse cardiovascular outcomes.
This indicates that the effects of various progestogens
on cardiovascular risk factors require further evaluation.
The aim of this study was not only to evaluate the
effect of hormone replacement therapy (HRT) on car-
diovascular risk factors, including lipoprotein metabo-
lism and hemostatic factors, but also to compare the
effects between natural progesterone and progestin.
Materials and Methods
Subjects
From January 1997 to December 1998, a total of 60
healthy postmenopausal women with climacteric
syndrome and without evidence of gynecologic disor-
ders voluntarily joined this study. All women had been
amenorrheic for 1 year or longer or had a plasma
estradiol level of less than 40 pg/mL and a plasma
follicular stimulating hormone level of more than
30 mIU/mL. They had not received HRT for at least
3 months prior to enrollment and had no contra-
indications for estrogen or progestogen treatment.
None had a history of significant medical disease, such
as diabetes mellitus, chronic liver disease, athero-
sclerosis, hypertension, thromboembolism, or infec-
tious disease, nor had any subject received medica-
tion that could affect the evaluation. All were non-
smokers. Women with the following conditions were
excluded from the trial: bleeding of undiagnosed
cause, oncotic colpocytology, findings suggesting
malignant disease of the breast, known or suspected
estrogen-dependent tumors or fibroids, alcoholism,
Rotor or Dubin-Johnson syndrome, severe liver or kid-
ney disorders, and endometrial hyperplasia. Written
informed consent was obtained from all subjects. This
protocol was approved by the Ethical Medicine Com-
mittee at our hospital.
Medication
Patients were assigned to one of three treatment groups.
Group I, consisting of 20 women who had undergone a
hysterectomy, received 0.625 mg/day conjugated equine
estrogen (CEE) (Premarin®, Wyeth-Ayerst Canada,
Montreal, Quebec, Canada). The remaining 40 women
were randomly assigned to one of the other two treatment
regimens. Group II (n = 20) received sequential combined
0.625 mg/day CEE for 21 days plus 200 mg/day micro-
nized progesterone (MP; Utrogestan®, Laborato-
ries Besins-Iscovesco, Paris, France) for the final 10
days (days 11 to 21) and then no medication for 7
days. Group III (n = 20) received sequential combined
0.625 mg/day CEE for 21 days plus 10 mg/day medroxy-
progesterone acetate (MPA; Provera®, Pharmacia &
Upjohn Company, Kalamazoo, MI, USA) for the final
10 days (days 11 to 21) and then no medication for
7 days. All patients completed a 12-cycle HRT course.
Laboratory tests
Fasting blood samples were collected before treatment
and at 24 and 48 weeks. Blood samples were drawn
from an antecubital vein using a 20-gauge needle and
were placed in anticoagulant solution (9 mL of whole
blood to 1 mL of 3.8% sodium citrate solution). Citrated
plasma was prepared for measurement of coagulation
and fibrinolytic markers by centrifugation at 4°C for
20 minutes at 1,600g, and samples were stored at –80°C
before use. Serum was isolated and stored at 4°C for
evaluation of the lipoprotein profile.
Total cholesterol and triglyceride concentrations
were determined using an enzymatic method with
an automatic analyzer (Beckman Synchron CX 7,
Beckman Coulter Inc, Fullerton, CA, USA). High-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), and very low-density lipoprotein
cholesterol (VLDL-C) levels were determined by an
electrophoretical method, using the HDL Cholesterol
Supply Kit (Helena Laboratory, Beaumont, TX, USA).
Plasma concentrations of tissue plasminogen
activator (TPA) and plasminogen activator inhibitor-1
(PAI-1) were determined by enzyme immunoassay
(BIA-t-PA, Chromogenix, Mölndal, Sweden; and
Thrombonostika PAI-1, Organon Teknika, Boxtel,
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Holland, respectively). The plasma levels of fibrinogen,
factor VII, and protein S were established using a clotting
assay (Fibrinogen Assay, Dade Diagnostico, Aguada,
Puerto Rico, USA; Factor VII DP, Behringwerke, Marburg,
Germany; and StaClot Protein S, Diagnostica Stago,
Asnieres-Sur-Seine, France; respectively). Concentrations
of antithrombin III and protein C were determined using
a chromogenic assay (Berichrom® Antithrombin III,
Dade Behring SA, Paris la Defense, France; and
Berichrom® Protein C, Dade Behring AG, Düdingen,
Switzerland, respectively).
Statistical methods
Data are expressed as mean ± standard deviation. Data
were analyzed using the Wilcoxon signed-rank test
to compare each variable before and after medication
within each group. Treatment group comparisons for
differences from baseline results were made using the
Kruskal-Wallis test and further by post hoc multiple
comparisons (Wilcoxon 2-sample test). Statistical
significance was accepted at p less than 0.05.
Results
Study population
Patient characteristics, including age, body mass index,
and duration of menopause, were similar in all groups
(Table 1). In addition, lipoprotein profiles and hemo-
static factors before HRT did not differ significantly
among the three groups.
Lipid profile
Changes in the lipid profiles in the three groups are
shown in Table 2. After 12 months of treatment, there
were no significant changes in total cholesterol or HDL-
C within the three groups. The LDL-C levels (p < 0.0001
and p = 0.042 at 6 and 12 months, respectively) and the
atherogenic ratios of total cholesterol/HDL-C (p = 0.02
at 6 months) and LDL-C/HDL-C (p < 0.001 and p =
0.004 at 6 and 12 months, respectively) were significantly
reduced with CEE (group I), whereas there were no
statistically significant changes with combined HRT
(groups II and III). There was a significant difference in
LDL-C, total cholesterol/HDL-C, and LDL-C/HDL-C
between groups I and II (p = 0.02) as well as between
groups I and III (p = 0.01), but no differences were noted
between groups II and III. Triglyceride levels increased
significantly in group I (p = 0.01 and p = 0.007 at 6 and
12 months, respectively), whereas with combined HRT
(groups II and III), there were no statistically significant
changes. After 12 months of treatment, the difference in
triglycerides was statistically significant between groups
I and II (p = 0.01), but not between groups I and III
(p = 0.31) or between groups II and III (p = 0.12).
Hemostatic factors
Hemostatic data are shown in Table 3. After 12 months
of CEE treatment (group I), TPA concentrations were
reduced (p = 0.007 and p < 0.001 at 6 and 12 months,
respectively), whereas the TPA levels did not change in
patients treated with combined HRT (groups II and III).
Although there was no statistically significant decrease
in PAI-1, the reduction in PAI-1 was more pronounced
in group I than in groups II and III. There were no
significant differences in TPA and PAI-1 among the
three groups.
After 12 months, there were no statistically signifi-
cant changes in fibrinogen or factor VII in any of the
three groups. Differences in factor VII were statistically
significant between groups I and II (p = 0.004), as well
as between groups I and III (p = 0.04).
In group I, antithrombin III (p = 0.007) and protein
S (p = 0.002) were reduced after 6 months but were
not changed after 12 months. After 12 months of
combined HRT, antithrombin III increased (group II:
p = 0.002; group III: p = 0.03). There was a significant
difference in antithrombin III between groups I and II
(p = 0.01). At 6 months, protein S had increased in
group III (p = 0.021). There was a statistical difference
in protein S between groups I and II (p = 0.004), as
well as between groups I and III (p < 0.001). The in-
crease in protein C was more pronounced in patients
in group I (p < 0.001) than in those treated with com-
bined HRT (groups II and III). There was a statis-
tically significant difference in protein C between
Table 1. Patient characteristics for three hormone replacement therapy groups
Group Age (yr) Period of menopause (yr) Body mass index (kg/m2)
I 50.5 ± 3.2 (45–55) 4.9 ± 3.5 (2–14) 25.8 ± 3.9
II 53.1 ± 3.3 (46–57) 4.2 ± 2.4 (2–10) 23.0 ± 2.7
III 50.1 ± 3.6 (45–55) 3.9 ± 2.6 (2–9)q 23.8 ± 4.0
Values are mean ± standard deviation (range). I = conjugated equine estrogen (CEE) alone; II = CEE plus micronized progesterone; III = CEE plus
medroxyprogesterone acetate.
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groups I and II (p = 0.002 and p < 0.001 at 6 and 12
months, respectively), as well as between groups I
and III (p = 0.02 and p = 0.002 at 6 and 12 months,
respectively). There was no statistical difference in
protein C between groups II and III (p = 0.22 and p =
0.12 at 6 and 12 months, respectively).
Discussion
Our results provide experimental evidence which
confirms the findings of many other studies, that estro-
gen replacement therapy (ERT) has beneficial effects
on the lipid profile and fibrinolytic factors in postmeno-
pausal women, and that these effects are diminished
by the addition of progestins. There was no significant
difference in these effects when using MP or MPA. How-
ever, the 1-year effects of ERT or HRT on the overall
factors related to venous thromboembolism remained
positive.
This study was performed in a comparative and
partially randomized (only groups II and III) fashion,
and all blood samples were analyzed by the same
laboratory according to the latest guidelines. The sam-
ple size fulfilled the minimum requirements for statis-
tical analysis.
This study provides the most unequivocal evidence
to date that unopposed estrogen has a more favorable
effect on lipoprotein metabolism than estrogen com-
bined with natural or synthetic progestogens. In post-
menopausal women receiving HRT, mean LDL-C lev-
els and atherogenic indices (total cholesterol/HDL-C
and LDL-C/HDL-C) were significantly lowered, more
so in patients treated with CEE alone than in those re-
ceiving CEE plus MPA or MP. In addition, the study
showed that treatment with CEE alone had a more
favorable effect on HDL-C than treatment with CEE
combined with progestogens, although the differences
did not reach statistical significance. These results are
in concordance with the Postmenopausal Estrogen/
Table 2. Effects of three hormone replacement therapy regimens on lipoprotein profile
I II III
Mean ± SD % change Mean ± SD % change Mean ± SD % change
p*
Total cholesterol (mg/dL)
   Baseline 223.6 ± 28.0 212.1 ± 28.5 219.4 ± 31.6
   6 months 214.5 ± 34.6 –4.1 202.3 ± 28.0 –4.6 217.4 ± 28.8 –0.9 0.531
   12 months 212.7 ± 25.4 –4.9 206.7 ± 23.9 –2.5 207.3 ± 26.1 –5.5 0.757
Triglycerides (mg/dL)
   Baseline 184.4 ± 29.0 176.0 ± 24.3 176.1 ± 26.3
   6 months 110.6 ± 46.7 31.1a 168.1 ± 28.3 –10.4 176.1 ± 34.3 –0.1 0.131
   12 months 117.3 ± 70.1 39.0b 164.6 ± 26.0 –14.9 186.6 ± 47.3 13.8 0.039
HDL-C (mg/dL)
   Baseline 153.1 ± 13.4 163.8 ± 16.1 160.9 ± 14.7
   6 months 157.4 ± 14.1 8.1 163.1 ± 15.3 –1.1 156.9 ± 13.4 –6.5 0.18
   12 months 156.1 ± 12.9 5.7 163.3 ± 19.0 –0.8 163.4 ± 14.4 14.2 0.66
LDL-C (mg/dL)
   Baseline 152.1 ± 26.8 133.6 ± 29.5 143.7 ± 38.1
   6 months 132.0 ± 31.4 –13.2c 126.1 ± 27.9 –5.6 143.3 ± 28.8 –0.3 0.041
   12 months 135.7 ± 24.7 –10.8d 141.9 ± 26.5 6.2 142.6 ± 34.1 –0.8 0.042
Cholesterol/HDL-C
   Baseline 14.5 ± 1.3 13.5 ± 0.8 13.8 ± 1.1
   6 months 14.0 ± 1.1 –9.9e 13.4 ± 0.8 –3.8 14.0 ± 1.1 16.4 0.019
   12 months 14.0 ± 1.0 –11.1 13.7 ± 1.0 4.9 13.7 ± 1.1 –0.8 0.068
LDL-C/HDL-C
   Baseline 13.1 ± 1.0 12.2 ± 0.6 12.5 ± 1.0
   6 months 12.5 ± 0.9 –18.4c 12.1 ± 0.8 –3.9 12.7 ± 1.0 16.7 0.001
   12 months 12.5 ± 0.8 –18.8f 12.4 ± 0.8 9.7 12.4 ± 0.9 –4.2 0.011
*Kruskal-Wallis test on change from baseline among groups. Wilcoxon signed-rank test compares results before and after medication within each group:
ap = 0.01; bp = 0.007; cp < 0.001; dp = 0.042; ep = 0.02; fp = 0.004. I = conjugated equine estrogen (CEE) alone; II = CEE plus micronized progesterone;
III = CEE plus medroxyprogesterone acetate; SD = standard deviation; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.
Taiwanese J Obstet Gynecol • June 2004 • Vol 43 • No 284
L.F. Teng, et al
Progestin Interventions (PEPI) study [6], in which the
beneficial effects on lipoprotein profiles, except tri-
glycerides, induced by unopposed estrogen were mildly
blunted by the addition of progestogens, including
MPA and MP. Although some reports have suggested
that natural progesterone has no significant effect on
plasma levels of lipoprotein [9,10], no significant dif-
ference in lipoprotein metabolism was noted between
patients receiving MPA and MP in the present study as
well as in the PEPI trial [6].
Our results are compatible with those of other studies
[2,9,11,12], in which the use of CEE alone increased the
plasma triglyceride level in postmenopausal women. An
increase in serum triglyceride concentration might have
been expected due to the ability of oral estrogen to
induce a modest increase in hepatic VLDL secretion,
particularly of large VLDL. Large VLDL is directly cata-
bolized by the liver rather than delipidated to small
VLDL and LDL, and therefore increased concentrations
might not be atherogenic. This also confirms the find-
ings of several previous studies [2,12–14], but not all
[6,15], which found that MPA or MP blunts this effect.
In this study, although triglyceride levels increased
non-significantly in the MPA group after 12 months
of treatment, there was no statistical difference in tri-
glyceride levels between the MPA and MP groups.
Since lipoprotein lipase is primarily responsible for the
degradation of triglyceride-rich lipoprotein, the most
visible consequences of high lipoprotein lipase activity
are low total triglyceride and high HDL-C plasma levels.
Table 3. Effects of three hormone replacement therapy regimens on hemostatic factors
I II III
Mean ± SD % change Mean ± SD % change Mean ± SD % change
p*
TPA (ng/mL)
   Baseline 13.8 ± 1.5 13.4 ± 1.3 13.5 ± 0.9
   6 months 12.7 ± 0.7 –30.2a 13.0 ± 1.5 –11.5 13.9 ± 0.9 15.0 0.558
   12 months 12.7 ± 0.6 –29.4b 12.8 ± 1.3 –17.9 13.4 ± 1.2 –6.4 0.671
PAI-1 (ng/mL)
   Baseline 17.6 ± 6.7 19.8 ± 6.1 19.8 ± 6.7
   6 months 10.2 ± 5.6 –42.1 18.2 ± 4.2 –15.9 18.7 ± 5.6 –11.6 0.377
   12 months 10.3 ± 4.2 –41.5 16.4 ± 4.4 –34.3 18.7 ± 6.9 –11.1 0.434
Fibrinogen (ng/mL)
   Baseline 266.4 ± 51.3 279.6 ± 49.5 257.9 ± 40.4
   6 months 254.1 ± 32.0 –4.6 286.7 ± 47.2 2.5 270.4 ± 40.1 4.9 0.398
   12 months 278.4 ± 45.1 4.5 282.9 ± 44.1 1.2 264.4 ± 36.0 2.5 0.600
Factor VII (%)
   Baseline 114.1 ± 13.8 122.5 ± 18.5 108.9 ± 21.4
   6 months 120.3 ± 27.3 5.4 116.3 ± 19.3 –5.1 110.3 ± 16.0 1.2 0.225
   12 months 1123.5 ± 121.2 8.2 111.4 ± 19.6 –9.1 100.7 ± 22.0 –7.6 0.014
Antithrombin III (%)
   Baseline 97.6 ± 8.7 99.0 ± 7.5 195.9 ± 9.91
   6 months 92.4 ± 8.2 –5.3c 101.2 ± 11.1 2.2 97.0 ± 7.4 1.2 0.039
   12 months 198.6 ± 13.2 1.1 106.7 ± 10.9 7.8d 102.7 ± 5.51 7.1e 0.057
Protein C (%)
   Baseline 193.5 ± 17.1 109.2 ± 20.1 100.4 ± 15.1
   6 months 127.1 ± 20.5 36.0b 114.2 ± 24.8 4.6 110.4 ± 18.5 10.0 0.004
   12 months 135.0 ± 24.7 44.4b 113.1 ± 20.9 3.6 120.1 ± 18.0 19.7f 0.000
Protein S (%)
   Baseline 192.9 ± 17.3 183.9 ± 14.6 80.7 ± 5.3
   6 months 180.1 ± 17.9 –13.8g 192.5 ± 13.5 10.2 192.3 ± 12.2 14.3h 0.001
   12 months 194.5 ± 16.1 1.7 195.1 ± 16.2 13.3 190.9 ± 16.8 12.7 0.201
*Kruskal-Wallis test on change from baseline among groups. Wilcoxon signed-rank test compares results before and after medication within each group:
ap = 0.007; bp < 0.001; cp = 0.007; dp = 0.002; ep = 0.03; fp = 0.011; gp = 0.002; hp = 0.021. I = conjugated equine estrogen (CEE) alone; II = CEE
plus micronized progesterone; III = CEE plus medroxyprogesterone acetate; SD = standard deviation; TPA = tissue plasminogen activator; PAI-1 = plasminogen
activator inhibitor-1.
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Based on our findings, it is possible that MPA may have
less of an effect on the activity of lipoprotein lipase than
MP, although this requires further evaluation.
Recent evidence reveals that impaired fibrinolytic
function, as evidenced by increased plasma con-
centrations of PAI-1 and TPA antigen, is associated
with coronary artery disease [16,17]. The explanation
for the association between a high level of TPA antigen
and a higher incidence of cardiovascular disease is
possibly related to the TPA antigen assay, which may
detect circulating complexes of inactive TPA and PAI-1
[18]. Observational studies have suggested an as-
sociation between HRT and increased fibrinolytic
potential [19–22], but experimental data are scarce.
Our study showed that unopposed oral CEE signifi-
cantly decreased TPA and PAI-1 levels. Prior studies
in postmenopausal women receiving estrogen
demonstrated improvement in fibrinolytic potential
consistent with our findings [21,23]. However, as re-
ported by Gebara et al [21], there were no significant
changes in TPA and PAI-1 concentrations between
CEE treatment alone and combined treatment with
CEE and progestin. In the present study, the addition of
progestogens slightly blunted the effects of CEE alone.
There were no differences in fibrinolytic factors between
the group receiving MPA and that receiving MP.
Some coagulation factors, such as fibrinogen and
factor VII, may play an important role in the pathogene-
sis of coronary artery disease [24]. Our study failed to
detect a statistically significant difference in changes in
fibrinogen levels among patients receiving CEE alone
(group I) and those using combined CEE with either MP
or MPA (groups II and III). This is compatible with the
PEPI trial [6] and other studies [25,26], in which there
was no significant difference in plasma fibrinogen
concentrations between active treatments. There are
conflicting results regarding factor VII. It has been
reported that factor VII increases with unopposed oral
CEE [25], but no significant changes occurred with
combined HRT [26,27]. However, our study, as well as
another randomized trial [28], demonstrated that high-
er factor VII activity was attributable to CEE alone as
compared with CEE combined with progestogen,
although there was no significant change in factor VII
during HRT in the present study. It has been suggested
that triglyceride activates phospholipase C-sensitive
factor VII complexes [29]. This suggestion is also sup-
ported by the report that the increase in triglyceride
levels during the use of oral CEE alone is responsible for
the parallel change in factor VII [2,28].
In a review of the literature on venous thrombosis,
we noted that conflicting results have been reported.
Prior to 1996, epidemiologic studies did not demon-
strate a positive association between ERT and ve-
nous thrombosis [29,30]. In contrast, four recent
observational studies reported that HRT increases the
risk of idiopathic venous thromboembolism [8,31–34].
These studies also demonstrated that the risk of venous
thromboembolism seemed to be restricted to the first
year of use, both in those with and without major risk
factors for venous thromboembolism [8,32–35]. How-
ever, there is still a lack of complete experimental eva-
luation of this condition. Deficiencies in antithrombin
III, protein C, and protein S can all predispose individuals
to venous thromboembolism. In our study, antithrombin
III and protein S were significantly reduced with CEE
alone in the first 6 months of treatment, as previously
reported [35,36], but returned to baseline levels after
12 months of HRT. In contrast, significant increases in
antithrombin III and protein S were noted with combined
HRT, which was compatible with our previous study of
postmenopausal women receiving estradiol valerate
plus MPA [37]. In the present study, the increase in
protein C was more pronounced in patients using CEE
alone than in those using combined HRT. However,
significant correlations were observed among protein S,
protein C, antithrombin III, factor VII, and fibrinogen,
which are factors related to thromboembolism. The net
effect after 1 year of ERT or combined HRT in this study
was compatible with the concept that HRT causes no
appreciable increase in venous thromboembolism over
the long term. These experimental results conflict with
the observational studies of HERS [8] and the Women’s
Health Initiative (WHI) [38], in which elderly women
receiving CEE plus MPA had an increased incidence of
venous thromboembolism after about a 5-year follow-
up. Since there was a lack of experimental data to show
the changes in coagulational and anticoagulational
factors in patients in HERS and WHI, whether the
differences between our study and HERS or WHI are
related to the conditions of patients, such as women
with existing cardiovascular disease or age, or duration
of follow-up, requires further evaluation. However, from
the present experimental data, the possibility of an
increased risk of venous thromboembolism in the first
year of ERT should still be considered.
In conclusion, this study confirms that ERT may
have a cardioprotective effect in postmenopausal
women, based on positive effects on lipoprotein and
fibrinolytic activity. The addition of both natural and
synthetic progestogens attenuated the effects of es-
trogen on lipoprotein and fibrinolytic factors, but still
resulted in beneficial effects on triglycerides. The 1-year
effects of hormone therapy on overall factors related
to venous thromboembolism were positive. Further-
more, MP was not superior to MPA.
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